Cargando…

Seroprevalence of SARS-CoV-2–Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence in cancer patients may vary widely dependent on the geographic area and this has significant implications for oncological care. The aim of this observational, prospective study was to assess the seroprevalence of SARS-CoV-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Cantini, Luca, Bastianelli, Lucia, Lupi, Alessio, Pinterpe, Giada, Pecci, Federica, Belletti, Giovanni, Stoico, Rosa, Vitarelli, Francesca, Moretti, Marco, Onori, Nicoletta, Giampieri, Riccardo, Rocchi, Marco Bruno Luigi, Berardi, Rossana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038489/
https://www.ncbi.nlm.nih.gov/pubmed/33916569
http://dx.doi.org/10.3390/jcm10071503
_version_ 1783677387259510784
author Cantini, Luca
Bastianelli, Lucia
Lupi, Alessio
Pinterpe, Giada
Pecci, Federica
Belletti, Giovanni
Stoico, Rosa
Vitarelli, Francesca
Moretti, Marco
Onori, Nicoletta
Giampieri, Riccardo
Rocchi, Marco Bruno Luigi
Berardi, Rossana
author_facet Cantini, Luca
Bastianelli, Lucia
Lupi, Alessio
Pinterpe, Giada
Pecci, Federica
Belletti, Giovanni
Stoico, Rosa
Vitarelli, Francesca
Moretti, Marco
Onori, Nicoletta
Giampieri, Riccardo
Rocchi, Marco Bruno Luigi
Berardi, Rossana
author_sort Cantini, Luca
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence in cancer patients may vary widely dependent on the geographic area and this has significant implications for oncological care. The aim of this observational, prospective study was to assess the seroprevalence of SARS-CoV-2 IgM/IgG antibodies in solid cancer patients referred to the academic institution of the Marche Region, Italy, between 1 July and 26 October 2020 and to determine the accuracy of the rapid serological test. After performing 3767 GCCOV-402a rapid serological tests on a total of 949 patients, seroconversion was initially observed in 13 patients (1.4%). Ten (77% of the total positive) were IgG-positive, 1 (8%) were IgM-positive and 2 (15%) IgM-positive/IgG-positive. However, only 7 out of 13 were confirmed as positive at the reference serological test (true positives), thus seroprevalence after cross-checking was 0.7%. No false negatives were reported. The kappa value of the consistency analysis was 0.71. Due to rapid serological test high false positive rate, its role in assessing seroconversion rate is limited, and the standard serological tests should remain the gold standard. However, as rapid test negative predictive value is high, GCCOV-402a may instead be useful to monitor patient immunity over time, thus helping to assist ongoing vaccination programs.
format Online
Article
Text
id pubmed-8038489
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80384892021-04-12 Seroprevalence of SARS-CoV-2–Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy Cantini, Luca Bastianelli, Lucia Lupi, Alessio Pinterpe, Giada Pecci, Federica Belletti, Giovanni Stoico, Rosa Vitarelli, Francesca Moretti, Marco Onori, Nicoletta Giampieri, Riccardo Rocchi, Marco Bruno Luigi Berardi, Rossana J Clin Med Article Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence in cancer patients may vary widely dependent on the geographic area and this has significant implications for oncological care. The aim of this observational, prospective study was to assess the seroprevalence of SARS-CoV-2 IgM/IgG antibodies in solid cancer patients referred to the academic institution of the Marche Region, Italy, between 1 July and 26 October 2020 and to determine the accuracy of the rapid serological test. After performing 3767 GCCOV-402a rapid serological tests on a total of 949 patients, seroconversion was initially observed in 13 patients (1.4%). Ten (77% of the total positive) were IgG-positive, 1 (8%) were IgM-positive and 2 (15%) IgM-positive/IgG-positive. However, only 7 out of 13 were confirmed as positive at the reference serological test (true positives), thus seroprevalence after cross-checking was 0.7%. No false negatives were reported. The kappa value of the consistency analysis was 0.71. Due to rapid serological test high false positive rate, its role in assessing seroconversion rate is limited, and the standard serological tests should remain the gold standard. However, as rapid test negative predictive value is high, GCCOV-402a may instead be useful to monitor patient immunity over time, thus helping to assist ongoing vaccination programs. MDPI 2021-04-04 /pmc/articles/PMC8038489/ /pubmed/33916569 http://dx.doi.org/10.3390/jcm10071503 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cantini, Luca
Bastianelli, Lucia
Lupi, Alessio
Pinterpe, Giada
Pecci, Federica
Belletti, Giovanni
Stoico, Rosa
Vitarelli, Francesca
Moretti, Marco
Onori, Nicoletta
Giampieri, Riccardo
Rocchi, Marco Bruno Luigi
Berardi, Rossana
Seroprevalence of SARS-CoV-2–Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy
title Seroprevalence of SARS-CoV-2–Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy
title_full Seroprevalence of SARS-CoV-2–Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy
title_fullStr Seroprevalence of SARS-CoV-2–Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy
title_full_unstemmed Seroprevalence of SARS-CoV-2–Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy
title_short Seroprevalence of SARS-CoV-2–Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy
title_sort seroprevalence of sars-cov-2–specific antibodies in cancer patients undergoing active systemic treatment: a single-center experience from the marche region, italy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038489/
https://www.ncbi.nlm.nih.gov/pubmed/33916569
http://dx.doi.org/10.3390/jcm10071503
work_keys_str_mv AT cantiniluca seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly
AT bastianellilucia seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly
AT lupialessio seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly
AT pinterpegiada seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly
AT peccifederica seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly
AT bellettigiovanni seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly
AT stoicorosa seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly
AT vitarellifrancesca seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly
AT morettimarco seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly
AT onorinicoletta seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly
AT giampieririccardo seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly
AT rocchimarcobrunoluigi seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly
AT berardirossana seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly